Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study.

Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM.

J Comput Assist Tomogr. 2019 May 6. doi: 10.1097/RCT.0000000000000866. [Epub ahead of print]

PMID:
31082984
2.

Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study.

Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM.

J Comput Assist Tomogr. 2019 May/Jun;43(3):499-506. doi: 10.1097/RCT.0000000000000866.

PMID:
31082956
3.

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma.

Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A.

Oncotarget. 2018 Dec 28;9(102):37721-37732. doi: 10.18632/oncotarget.26507. eCollection 2018 Dec 28.

4.

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M.

J Hematol Oncol. 2018 May 30;11(1):71. doi: 10.1186/s13045-018-0616-2.

5.

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma.

Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, Kaseb A, Sheth RA.

J Clin Med. 2018 Apr 14;7(4). pii: E83. doi: 10.3390/jcm7040083.

6.

Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.

Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC).

Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13. Erratum in: Lancet Gastroenterol Hepatol. 2018 Jun;3(6):e3.

PMID:
29548617
7.

Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.

Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO.

Oncology. 2017;93(4):233-242. doi: 10.1159/000455957. Epub 2017 Jul 6.

PMID:
28683459
8.

Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma.

Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO.

Clin Gastroenterol Hepatol. 2017 Nov;15(11):1791-1799. doi: 10.1016/j.cgh.2017.05.036. Epub 2017 Jun 1.

9.

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?

Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO.

Onco Targets Ther. 2017 Mar 3;10:1403-1412. doi: 10.2147/OTT.S111681. eCollection 2017. Review.

10.

Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour I, Tabash A, Abdel-Wahab R, Abousamra AO, Shaw KR, Xiao L, Hassan MM, Kipp BR, Kopetz S, Soliman AS, McWilliams RR, Wolff RA.

J Gastrointest Oncol. 2016 Dec;7(6):882-902. doi: 10.21037/jgo.2016.11.02.

11.

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):969-978. doi: 10.1007/s00259-016-3583-2. Epub 2016 Dec 12.

12.

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T.

Oncotarget. 2016 Oct 25;7(43):69916-69926. doi: 10.18632/oncotarget.12066.

13.

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma.

Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO.

J Hepatocell Carcinoma. 2016 Feb 5;3:1-7. doi: 10.2147/JHC.S62261. eCollection 2016.

14.

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.

Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC.

Onco Targets Ther. 2016 Feb 15;9:773-80. doi: 10.2147/OTT.S91977. eCollection 2016.

15.

Reply: To PMID 25836985.

Hassan MM, Abdel-Wahab R, Li D, Kaseb AO.

Gastroenterology. 2015 Nov;149(6):1643-4. doi: 10.1053/j.gastro.2015.09.035. Epub 2015 Oct 1. No abstract available.

PMID:
26433110
16.

Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.

Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO.

Oncotarget. 2015 Aug 28;6(25):21193-207.

17.

Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma.

Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D.

Gastroenterology. 2015 Jul;149(1):119-29. doi: 10.1053/j.gastro.2015.03.044. Epub 2015 Mar 30.

18.

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma.

Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO.

J Hepatocell Carcinoma. 2015 Sep 18;2:131-42. doi: 10.2147/JHC.S81309. eCollection 2015. Review.

19.

A giant rectal villous adenoma with a malicious intent.

Aboul Hosn M, Abdel-Hafiez N, Abdel-Wahab R, Al-Ahmadie A, Antar A, Dbouk H, El Farran H, El-Sawy Mohamed M, Rida K, Mukherji D, O'Reilly EM, Garcia-Aguilar J, Abou-Alfa GK.

Gastrointest Cancer Res. 2013 Sep;6(5-6):144-9. No abstract available.

Supplemental Content

Loading ...
Support Center